Refractory Classic Hodgkin Lymphoma

13 clinical trials · Condition

Record	Firm	Date
CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or Relapsed (NCT05162976)	City of Hope Medical Center	2022-01-03
Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas (NCT04074746)	M.D. Anderson Cancer Center	2020-07-18
Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. (NCT03150329)	City of Hope Medical Center	2017-07-18
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer (NCT02595866)	National Cancer Institute (NCI)	2016-04-04
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (NCT02408861)	National Cancer Institute (NCI)	2015-10-21
Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (NCT01896999)	National Cancer Institute (NCI)	2014-03-07

Every clearance here is in the API, with alerts when new ones post.